amikacin + mannitol

This is an investigational combination therapy consisting of a reduced dose of amikacin (500 mg) and mannitol (5 g), developed by the Centre Hospitalier Universitaire Vaudois (CHUV). It is being evaluated in the UROPOT clinical trial for the prevention of urinary tract infections in patients with ureteral stents and asymptomatic bacteriuria undergoing endourological procedures. Amikacin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Mannitol acts as a metabolic potentiator, stimulating bacterial metabolism to increase the uptake and efficacy of the aminoglycoside, particularly against persistent forms like biofilms. This strategy aims to maintain antimicrobial efficacy while reducing the dose of amikacin to minimize potential nephrotoxicity and ototoxicity.

Other names

mannitol-potentiated amikacinmannitol-enhanced amikacinmannitol-enhanced low-dose amikacin